Data updated: Mar 29, 2026

LAVIPHARM

Cardiovascular

Specialty

LAVIPHARM is a specialty pharmaceutical company focused on Cardiovascular.

1984

Since

7

Drugs

-

Trials

10

Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues ProEarly access

Loading...

Revenue Over Time ProEarly access

Loading...

Recent Activity

FENTANYL-75 2025-12-22

FENTANYL-75 2025-12-22

FENTANYL-100 2025-12-22

FENTANYL-75 2025-12-22

FENTANYL-75 2025-12-22

FENTANYL-100 2025-12-22

FENTANYL-75 2024-10-31

FENTANYL-100 2024-10-31

SEC Filings ProEarly access

Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 100%

3 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones ProEarly access

Loading...

Patent Cliff ProEarly access

Loading...

Competitors by Therapeutic Area

Novartis big-pharma

Merck big-pharma

Baxter specialty

Johnson & Johnson big-pharma

Bayer big-pharma